Increased expression of interleukin‐17 pathway genes in nonlesional skin of moderate‐to‐severe psoriasis vulgaris

Psoriasis vulgaris is an inflammatory immune‐mediated disease, with lesional skin characterized by sharply demarcated, erythematous scaly plaques. Uninvolved psoriatic skin appears clinically similar to normal skin. However, it has been hypothesized that inflammatory cytokines, e.g. interleukin (IL)‐17, may affect any organ or tissue having a vascular supply; thus, distant uninvolved skin could be exposed to increased circulating IL‐17.

[1]  D. Shrom,et al.  IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. , 2014, The Journal of investigative dermatology.

[2]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[3]  M. Suárez-Fariñas,et al.  IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model , 2014, PloS one.

[4]  David A. Martin,et al.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. , 2013, Trends in immunology.

[5]  Jennifer E Towne,et al.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. , 2013, The Journal of investigative dermatology.

[6]  Andrew Johnston,et al.  Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients , 2013, BMC Genomics.

[7]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[8]  Suyan Tian,et al.  Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.

[9]  Mayte Suárez-Fariñas,et al.  Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.

[10]  J. Gudjonsson,et al.  A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin. , 2012, The Journal of investigative dermatology.

[11]  Alan Menter,et al.  A subset of methylated CpG sites differentiate psoriatic from normal skin , 2011, The Journal of investigative dermatology.

[12]  Scott B. Dewell,et al.  Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes , 2011, The Journal of investigative dermatology.

[13]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[14]  A. Blauvelt,et al.  IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicans , 2010, The Journal of Immunology.

[15]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[16]  Andrew Johnston,et al.  Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. , 2010, The Journal of investigative dermatology.

[17]  A. Blauvelt,et al.  Circulating Th17, Th22, and Th1 cells are increased in psoriasis. , 2010, The Journal of investigative dermatology.

[18]  Mayte Suárez-Fariñas,et al.  Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA) , 2010, PloS one.

[19]  A. Ishida-Yamamoto,et al.  Serum cytokines and growth factor levels in Japanese patients with psoriasis , 2009, Clinical and experimental dermatology.

[20]  Xing Li,et al.  Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. , 2009, The Journal of investigative dermatology.

[21]  Pilar Romero,et al.  IL‐17‐producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17‐related cytokines , 2009, Journal of leukocyte biology.

[22]  J. Krueger,et al.  Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases , 2009, Journal of Clinical Immunology.

[23]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[24]  E. Antiga,et al.  Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial , 2009, Journal of Clinical Immunology.

[25]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[26]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[27]  Erin G Harper,et al.  Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines , 2007, Current rheumatology reports.

[28]  R. Steinman,et al.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.

[29]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[30]  L. Hennighausen,et al.  Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[33]  Sangsoo Kim,et al.  Combining multiple microarray studies and modeling interstudy variation , 2003, ISMB.

[34]  Wing Hung Wong,et al.  Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. , 2003, Physiological genomics.

[35]  F. Nestle,et al.  Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. , 1994, The Journal of clinical investigation.

[36]  R. Benner,et al.  The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a- antigen-presenting cells. , 1990, The Journal of investigative dermatology.

[37]  W. Placek,et al.  Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. , 1988, Acta dermato-venereologica.

[38]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[39]  H. Valdimarsson,et al.  Epidermal T lymphocytes and HLA‐DR expression in psoriasis , 1984, The British journal of dermatology.